Alto Neuroscience (ANRO) Total Liabilities (2023 - 2026)
Alto Neuroscience (ANRO) posted Total Liabilities of $32.9 million for Q1 2026, down 1.96% sequentially from $33.5 million in Q4 2025, and little changed YoY from $32.8 million in Q1 2025.
Alto Neuroscience (ANRO) Total Liabilities (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Total Liabilities for 4 years, with the latest figure at $32.9 million in Q1 2026.
- Quarterly Total Liabilities changed 0.22% year-over-year to $32.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.9 million (changed 0.22% YoY) and the FY2025 annual result came in at $33.5 million, up 28.62% from the prior year.
- Total Liabilities declined to $32.9 million in Q1 2026 per ANRO's latest filing, from $33.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $35.4 million in Q3 2025 and troughed at $16.8 million in Q1 2024.
- A 4-year average of $27.3 million and a median of $29.7 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities soared 96.0% in 2025, then gained 0.22% in 2026.
- Over 4 years, Total Liabilities stood at $16.8 million in 2023, then jumped by 55.04% to $26.1 million in 2024, then rose by 28.62% to $33.5 million in 2025, then declined by 1.96% to $32.9 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $32.9 million, $33.5 million, and $35.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 34.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.82 Mn |
| Mar 31, 2026 | 32.89 Mn |
| Dec 31, 2025 | 33.55 Mn |
| Sep 30, 2025 | 35.45 Mn |
| Jun 30, 2025 | 34.47 Mn |
| Mar 31, 2025 | 32.82 Mn |
| Dec 31, 2024 | 26.08 Mn |
| Sep 30, 2024 | 26.56 Mn |
| Jun 30, 2024 | 17.58 Mn |
| Mar 31, 2024 | 16.82 Mn |
| Dec 31, 2023 | 16.82 Mn |